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Background: CF patients often demonstrate hypersensitivity to one or multiple antibiotics due to frequent and repeated exposures. Attempts at
antibiotic desensitization in this population are historically complicated by higher reaction rates, failure to complete the procedure and consequent
withholding of first-line therapy. This study evaluates the outcomes of a rapid desensitization protocol developed at our institution.
Methods:We retrospectively reviewed the medical records of 15 patients undergoing 52 rapid antibiotic desensitizations at Brigham and Women's
Hospital and Children's Hospital Boston utilizing our protocol.
Results:Mean FEV1 % predicted was 44.1 (SD 16.5), with two patients at b30% and one patient desensitized during bilateral lung transplantation.
Adverse reactions during desensitization occurred in 13.4%, and most were mild. 100% of patients completed the protocol and ultimately tolerated
subsequent full-strength antibiotic courses.
Conclusions: CF patients with antibiotic hypersensitivity can safely receive first-line antibiotics via our rapid desensitization protocol, including
those with severe obstructive lung disease.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Antibiotic; Allergy; Hypersensitivity; Desensitization; Protocol1. Introduction
Patients with cystic fibrosis (CF) have a higher prevalence of
allergic reactions to one or multiple antibiotics, especially beta-
lactams, thought to be due in part to multiple and repeated
exposures. The worldwide prevalence of beta-lactam allergy in
CF patients has been reported as high as 36% [1], with as many
as 60% of Danish CF patients affected [2]. The high incidence
of pseudomonal infections, the consequent need to treat with
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doi:10.1016/j.jcf.2009.08.002specific anti-pseudomonal antibiotics and the risk of potentially
life-threatening allergic reactions to these medications often
complicate management in these patients.
Antibiotic desensitizations have been performed by allergists
to tolerize these patients to first-line therapy. However, several
factors have impeded their widespread utilization. The concept
of reintroducing highly allergenic medications into sensitized
individuals with significantly impaired lung function and, thus,
at a presumed increased risk for anaphylaxis [3] causes great
concern among pulmonologists regarding the safety of rapid
desensitization for their patients. This apprehension has been
supported by desensitization failure rates of approximately 25%
in previously published case series [4,5] characterized by severe
reactions during desensitizations, institution of life-saving
measures, discontinuation of the desensitization protocol and
switching to second-line therapy.
d by Elsevier B.V. All rights reserved.
Table 1
Patient characteristics and outcomes of desensitization.
Patient Age, sex Initial reaction FEV1 (L) (% predicted ) Lung
transplant
Antibiotic Skin
test
Desensitization
Protocol # of
courses (52)
Step/reaction Treatment Completed
1 46, F Urticaria,
angioedema
0.50–0.60 a (22–26) a Yes Meropenem nd 12 step,
250 mL bag
3 No – Yes
2 51, M Urticaria 2.19 (66) Yes TMP/SMX nd 12 step,
250 mL bag
1 No – Yes
3 29, F Urticaria 1.40 (43) Yes TMP/SMX nd 12 step,
250 mL bag
2 No – Yes
4 40, M Urticaria, tongue
swelling
0.47–0.90 (11–25) Yes Piperacillin/tazobactam – 12 step,
250 mL bag
1 No – Yes
12 step,
250 mL bag
1 Step 3: Urticaria,
sore throat
Diphenhydramine Yes
12 step,
250 mL bag
1 Step 12: Urticaria Diphenhydramine Yes
12 step,
250 mL bag
1 Step 12: Urticaria Diphenhydramine,
methylprednisolone
Yes
13 step,
250 mL bag
1 No – Yes
Urticaria,
angioedema
0.79 (20) Ceftazidime nd 12 step,
250 mL bag
1 No – Yes
16 step,
100 mL bag
1 No – Yes
5 22, F Urticaria, throat
swelling
1.17 (31) Yes Ceftazidime nd 16 step,
100 mL bag
2 No – Yes
Urticaria N/A TMP/SMX nd 16 step,
100 mL bag
1 No – Yes
6 35, F Urticaria,
throat pruritus
2.32 (77) No Ceftazidime + 12 step,
250 mL bag
1 No – Yes
Urticaria, lip
swelling
1.66–2.10 (56–72) Cefepime nd 16 step,
20 mL bag
3 No – Yes
12 step,
50 mL bag
3 No – Yes
7 21, F Urticaria 1.55 (49) No Cefoxitin nd 12 step,
250 mL bag
1 No – Yes
8 42, M Urticaria 1.52 (38) No Ceftazidime – 12 step, 1 No – Yes
(continued on next page)
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Table 1 (continued)
Patient Age, sex Initial reaction FEV1 (L) (% predicted ) Lung
transplant
Antibiotic Skin
test
Desensitization
Protocol # of
courses (52)
Step/reaction Treatment Completed
100 mL bag
9 21, F Urticaria 1.72–1.84 (54–58) No Piperacillin/tazobactam + 16 step,
100 mL bag
1 Nausea, diarrhea
flushing, erythema b
Diphenhydramine Yes
12 step,
250 mL bag
1 No – Yes
16 step,
100 mL bag
1 Urticaria, flushing b Diphenhydramine Yes
10 26, M Urticaria 1.11–2.02 (27–47) Yes Ceftazidime nd 12 step,
100 mL bag
4 No – Yes
12 step,
100 mL bag
1 Acute respiratory
failure b
Intubation Yes
12 step,
250 mL bag
2 No – Yes
12 step,
100 mL bag
1 No – Yes
Urticaria, dyspnea,
wheezing
1.11–2.02 (27–47) Piperacillin/tazobactam – 12 step,
250 mL bag
2 No – Yes
12 step,
100 mL bag
2 No – Yes
11 25, F Urticaria 1.81 (51) No Tobramycin nd 12 step,
200 mL bag
1 No – Yes
Urticaria 1.81 (51) Meropenem nd 12 step,
100 mL bag
1 No – Yes
12 26, M Urticaria 1.50–2.80 (32–61) No Ceftazidime + 12 step,
250 mL bag
2 No – Yes
12 step,
250 mL bag
1 Step 12: Urticaria Diphenhydramine Yes
13 29, M Urticaria 2.83 (65) No Ciprofloxacin nd 12 step,
250 mL bag
2 No – Yes
14 22, F Urticaria 1.70 (60) No Piperacillin/tazobactam – 12 step,
250 mL bag
1 No – Yes
15 c 49, F Urticaria,
scratchy throat
1.50 (49–50) No Ceftazidime nd 12 step,
100 mL bag
3 No – Yes
Urticaria, wheezing 1.50 (49) TMP/SMX nd 12 step, 1 No – Yes
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421H.J. Legere III et al. / Journal of Cystic Fibrosis 8 (2009) 418–424The primary aim of our study was to determine the efficacy of
a rapid intravenous antibiotic desensitization protocol originally
developed at our institution for chemotherapeutic agents [6–8].
We also wanted to assess the safety of our protocol in a high-risk
group of patients with moderate-to-severe obstructive lung
disease.
2. Methods
After obtaining IRB approval, we retrospectively reviewed the
medical records of all CF patients who underwent antibiotic
desensitization at Brigham and Women's Hospital (BWH) and
Children's Hospital Boston (CHB) from 1998 to 2009 using the
BWH protocol. Patients were determined to be amenable to rapid
desensitization based on a clinical history consistent with a type I
hypersensitivity reaction (HSR) and skin testing results when
available. Type I HSRs were defined as reactions occurring
during or shortly after an antibiotic infusion, and characterized by
the following signs and symptoms: cutaneous (flushing, pruritus,
urticaria, angioedema), cardiovascular (chest pain, tachycardia,
sense of impending doom, presyncope, syncope, hypertension,
hypotension), respiratory (sneezing, nasal congestion, dyspnea,
coughing, wheezing, oxygen desaturation), throat tightness,
gastrointestinal (nausea, vomiting, abdominal pain, diarrhea,
bloating), and neuromuscular (disorientation, hallucination,
vision disturbances, ringing/pounding in ears, unusual taste,
back pain, numbness/weakness). Patients who presented with a
maculopapular rash, delayed-type hypersensitivity, serum sick-
ness, erythema multiforme, Stevens–Johnson syndrome or toxic
epidermal necrolysis were excluded from consideration for
desensitization. Atopy was defined as the presence of allergic
rhinoconjunctivitis, food allergy, urticaria/angioedema, eczema
and/or latex allergy. Asthma was not included in the definition, as
the symptoms and objective findings in this pulmonary syndrome
are often difficult to distinguish from those of CF. Forced
expiratory volume at 1 s (FEV1) was obtained at the time closest
to that of the desensitization to determine the degree of obstructive
lung disease. The choice of antibiotic was determined by the
consulting pulmonologist based on first-line sensitivity to the
bacterial pathogen. The desensitization procedure was deemed
successful if the full antibiotic dose was administered.
After written consent was obtained prior to each procedure,
rapid intravenous desensitization was performed to the selected
antibiotic using the standard 12-step or 16-step protocol
developed for chemotherapeutic agents [6–8], subject to
modification based on reactions during prior desensitizations.
Diphenhydramine (25 mg oral or intravenous) and either
famotidine (20 mg intravenous) or ranitidine (50 mg intrave-
nous) were administered 20min before the initiation of the
protocol. Patients 12 and 14 received lorazepam 0.5–1 mg for
anxiety. Prior to the second desensitization course to ceftazi-
dime for Patient 4, both aspirin (325 mg oral) and montelukast
(10 mg oral) were administered 60min beforehand, as this
medication regimen has proven to be useful in patients with
refractory mast cell mediator-related symptoms [9]. Emergency
resuscitation equipment and standard medications (epinephrine,
methylprednisolone, albuterol, antihistamines and glucagon)were at the bedside. All initial desensitizations and 94% of
subsequent desensitizations were performed in the medical
intensive care unit (MICU) with 1:1 nursing. Following
successful desensitization, the antibiotic was continued in full
doses and at regularly-scheduled intervals for a treatment period
typically lasting 14 to 21 days.3. Results
As described in Table 1, we performed a total of 52
desensitizations in 15 patients, ranging from 1 to 12 desensiti-
zation courses per patient (mean 3.5), mean age 32.2 (21–49, SD
10.7), female tomale ratio 3:2. Nine of the 15 patients (60%)were
atopic and 12 (80%) were allergic to multiple antibiotics. Nine
different antibiotics were administered, with piperacillin and
ceftazidime being most common. Bilateral lung transplantation
was performed in six patients (40%), with one undergoing
desensitization intraoperatively. Desensitizations were performed
in patients with FEV1s ranging from 11 to 77% predicted (0.47–
2.83 L), with two patients consistently below 30% and a mean
FEV1 of 44.1% predicted (SD 16.5).
Fifty of 52 desensitizations (96.2%) were completed without
severe adverse events. Patient 9 developed nausea, diarrhea,
flushing and a generalized erythematous rash 15min after
completing desensitization and was successfully re-desensitized
with a modified protocol. Patient 10 developed acute respiratory
failure requiring intubation shortly after the procedure, an event
retrospectively attributed to worsening pulmonary infection.
Minor reactions in Patients 4, 9 and 12 (9.6%) consisted of
flushing, hives, nausea or diarrhea and were treated with
antihistamines and/or systemic corticosteroids. There were no
severe reactions that prevented completion of desensitization.
All patients received the full dose of the desired antibiotic,
regardless of FEV1 or transplant status. There was a slightly
higher rate of reactions during desensitization of patients with
lower FEV1 but they were mild, well-tolerated and easily
treated. Patients 4 and 8 completed desensitization using the
original 12-step protocol [6–8] but subsequently developed
flushing, urticaria and/or angioedema during administration of
the full-dose antibiotic. Patient 10 developed isolated dyspnea
during full-dose treatments that followed uncomplicated
desensitizations on two separate admissions. Matching the
final concentration of Solution 3 to the antibiotic concentration
used in non-desensitized patients allowed these patients to
tolerate the full antibiotic course (Fig. 1b).4. Discussion
As patients with CF live longer—due to improved therapeu-
tics, social support, availability of lung transplants—and have
more frequent exposures to antibiotics (some of which, such as
piperacillin, may be more immunogenic [2]) the prevalence of
allergy to antibiotics has increased and will continue to increase.
Drug desensitization is a safe and effective method to keep
patients on first-line, preferred therapy, even in those patients with
severely decreased lung function [10].
422 H.J. Legere III et al. / Journal of Cystic Fibrosis 8 (2009) 418–424While unsuccessful desensitizations have been reported in
24% [5] and 25% [4] of other series using empiric protocols, we
report a 100% desensitization completion rate using ourFig. 1. Examples of desensitization protocols using various target antibiotic concentra
using solution volumes of 100mL. (c) 16-step protocol using solution volumes of 2protocol with two systemic reactions that were amenable to
re-desensitization. Our results can be explained by the use of a
safe protocol modeled after an in vitro experimental systemtions. (a) 12-step protocol using solution volumes of 250mL. (b) 12-step protocol
0mL.
Fig. 1 (continued).
423H.J. Legere III et al. / Journal of Cystic Fibrosis 8 (2009) 418–424[11], the exclusion of patients with reactions not typical of type I
HSRs and perseverance through reactions during desensitiza-
tion procedures once the appropriate treatments and/or protocol
modifications have been instituted. Although the evaluation of
this protocol is ongoing, we have previously demonstrated its
success for both chemotherapeutic agents and monoclonal
antibodies in the largest reported case series [8].
Medications that require dosing intervals greater than 24h,
such as chemotherapy and monoclonal antibodies, need to be
administered by desensitization in sensitized individuals with
each treatment. Antibiotics, however, are dosed more fre-
quently—often several times a day—and, thus, need only be
administered by desensitization once per treatment course if the
desensitization is successful and subsequent doses areFig. 2. Pearls fromadministered in a timely fashion. In contrast to desensitization
to chemotherapeutic agents, where a final target dose must be
reached, our experience with CF patients who tolerated their
desensitization but subsequently reacted to a full-strength
antibiotic dose led us to modify our original protocol to a final
target dose and concentration. For example, Patients 4 and 10
were successfully desensitized to their HSR-inducing antibiotic
in a lower concentration solution (250-mL volume) than the
typical concentration for that antibiotic (50- or 100-mL
volume) and subsequently developed breakthrough reactions
when receiving their scheduled doses at the typical concentra-
tion. We consequently modified their protocols to adjust the
concentration of each bag during desensitization to match the
typical concentration of the antibiotic and successfully reducedour experience.
424 H.J. Legere III et al. / Journal of Cystic Fibrosis 8 (2009) 418–424breakthrough reactions with subsequent antibiotic doses given
at the typical concentration and schedule. We have since
adopted this strategy for desensitization of our non-CF patients
with antibiotic hypersensitivity, which has resulted in even
greater success [unpublished data]. We have also implemented
this approach to allow us to perform desensitizations in very
high-concentration (20-mL volume) home infusion pumps
(Fig. 1c).
The major limitation of this study is that clinical history has
almost exclusively guided our decision to perform desensitiza-
tion, as skin testing data was not routinely available due to the
lack of commercially-available testing reagents in the United
States since 2005. Without standardized reagents, the positive
and negative predictive values of skin testing for penicillin and
beta-lactams remain unknown and, thus, no patient seen after
2005 underwent skin testing. It should also be noted that the
decision on whether or not to modify the desensitization
protocol based on concentration often occurred in the setting of
an urgent or emergent consultation, when a detailed review of a
patient's prior history of desensitization protocols and reactions
was not always available. Since the establishment of our
desensitization program and the introduction of a longitudinal
electronic medical record system at our institution, we can now
access all prior desensitization records and, thus, be able to
evaluate and manage patients with previous histories of
reactions during desensitizations in a more standardized
fashion. Our ongoing studies seek to determine the clinically
relevant concentrations of various antibiotics in patients with
CF and to evaluate the implementation of our protocol as the
standard of care in order to safely provide patients with first-line
therapy.
5. Conclusions
Desensitizations to antibiotics in patients with CF are safe
using our protocol. We have had a 100% successful delivery of
the desired antibiotic in our patient population. We decreased the
percentage of reactions occurring during desensitization and
during subsequent doses by adjusting the final concentration of
the desensitization infusion to match the concentration that is
typically administered for non-allergic patients. Even the most
critically ill patients with extremely low FEV1 and/or imminent
lung transplant safely tolerated the procedure. Therefore, neither
lung function nor lung transplant status should be viewed as acontraindication to performing desensitization. Rather, clinicians
should focus on treating their patients' underlying infections with
first-line agents utilizing this procedure (Fig. 2).Acknowledgments
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